HK1247198A1 - 作為用於治療癌症的組蛋白脫甲基酶kdm2b的抑制劑的(呱啶-3-基)(萘-2-基)甲酮衍生物及其相關化合物 - Google Patents
作為用於治療癌症的組蛋白脫甲基酶kdm2b的抑制劑的(呱啶-3-基)(萘-2-基)甲酮衍生物及其相關化合物Info
- Publication number
- HK1247198A1 HK1247198A1 HK18106726.8A HK18106726A HK1247198A1 HK 1247198 A1 HK1247198 A1 HK 1247198A1 HK 18106726 A HK18106726 A HK 18106726A HK 1247198 A1 HK1247198 A1 HK 1247198A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- kdm2b
- naphthalen
- piperidin
- inhibitors
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562101927P | 2015-01-09 | 2015-01-09 | |
PCT/US2016/012638 WO2016112284A1 (en) | 2015-01-09 | 2016-01-08 | (piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1247198A1 true HK1247198A1 (zh) | 2018-09-21 |
Family
ID=55299746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18106726.8A HK1247198A1 (zh) | 2015-01-09 | 2018-05-24 | 作為用於治療癌症的組蛋白脫甲基酶kdm2b的抑制劑的(呱啶-3-基)(萘-2-基)甲酮衍生物及其相關化合物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10280149B2 (zh) |
EP (1) | EP3242872B1 (zh) |
JP (1) | JP6855379B2 (zh) |
CN (1) | CN107406414B (zh) |
HK (1) | HK1247198A1 (zh) |
WO (1) | WO2016112284A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3600287B1 (en) | 2017-03-29 | 2023-07-05 | Purdue Research Foundation | Inhibitors of kinase networks and uses thereof |
DK3765461T3 (da) * | 2018-03-14 | 2023-11-20 | Prelude Therapeutics Inc | Selektive protein argininmethyltransferase 5 (prmt5)-hæmmere |
EP4149917A1 (en) * | 2020-05-12 | 2023-03-22 | Merck Sharp & Dohme LLC | Factor xi activation inhibitors |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
LU77659A1 (de) * | 1977-06-30 | 1979-03-26 | Byk Gulden Lomberg Chem Fab | Piperidinoadamantane,verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
JP2975679B2 (ja) | 1989-09-08 | 1999-11-10 | ザ・ジョーンズ・ホプキンス・ユニバーシティ | ヒト神経膠腫のegf受容体遺伝子の構造変化 |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
ES2166368T3 (es) | 1993-12-24 | 2002-04-16 | Merck Patent Gmbh | Inmunoconjugados. |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
WO1996003397A1 (en) | 1994-07-21 | 1996-02-08 | Akzo Nobel N.V. | Cyclic ketone peroxide formulations |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
JP3088018B2 (ja) | 1995-03-30 | 2000-09-18 | ファイザー・インコーポレーテッド | キナゾリン誘導体 |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
EP0831880A4 (en) | 1995-06-07 | 2004-12-01 | Imclone Systems Inc | ANTIBODIES AND FRAGMENTS OF ANTIBODIES INHIBITING TUMOR GROWTH |
CZ1598A3 (cs) | 1995-07-06 | 1998-04-15 | Novartis Ag | Pyrrolopyrimidiny a způsoby jejich přípravy |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
DK0912559T3 (da) | 1996-07-13 | 2003-03-10 | Glaxo Group Ltd | Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
ES2201484T3 (es) | 1997-05-06 | 2004-03-16 | Wyeth Holdings Corporation | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
BR9814116A (pt) | 1997-11-06 | 2000-10-03 | American Cyanamid Co | Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico |
ATE229008T1 (de) | 1998-11-19 | 2002-12-15 | Warner Lambert Co | N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3- morfolin-4-yl-propoxy)-chinazolin-6-yl -akrylamid,ein irreversibler tyrosin-kinasen hemmer |
WO2001022964A1 (en) * | 1999-09-27 | 2001-04-05 | Georgetown University | Dopamine transporter inhibitors and their use |
PE20071079A1 (es) * | 2005-11-15 | 2007-12-16 | Cytokinetics Inc | Compuestos de piperidina como inhibidores de la proliferacion celular |
WO2010054279A1 (en) * | 2008-11-10 | 2010-05-14 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
WO2012071469A2 (en) * | 2010-11-23 | 2012-05-31 | Nevada Cancer Institute | Histone demethylase inhibitors and uses thereof for treatment o f cancer |
WO2013123411A1 (en) * | 2012-02-17 | 2013-08-22 | Board Of Regents, The University Of Texas System | Methods for diagnosing and treating cancer |
WO2014151106A1 (en) * | 2013-03-15 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
-
2016
- 2016-01-08 JP JP2017536302A patent/JP6855379B2/ja active Active
- 2016-01-08 EP EP16702830.7A patent/EP3242872B1/en active Active
- 2016-01-08 WO PCT/US2016/012638 patent/WO2016112284A1/en active Application Filing
- 2016-01-08 CN CN201680014364.2A patent/CN107406414B/zh active Active
-
2017
- 2017-07-07 US US15/643,808 patent/US10280149B2/en active Active
-
2018
- 2018-05-24 HK HK18106726.8A patent/HK1247198A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
JP2018501288A (ja) | 2018-01-18 |
JP6855379B2 (ja) | 2021-04-07 |
CN107406414A (zh) | 2017-11-28 |
US20180022727A1 (en) | 2018-01-25 |
EP3242872B1 (en) | 2019-07-03 |
EP3242872A1 (en) | 2017-11-15 |
CN107406414B (zh) | 2022-04-19 |
US10280149B2 (en) | 2019-05-07 |
WO2016112284A1 (en) | 2016-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181661T1 (hr) | Inhibitori jak1 za liječenje mijelodisplastičnih sindroma | |
HK1253559A1 (zh) | 作為組蛋白脫甲基酶抑制劑的吡咯烷酰胺化合物 | |
HK1258779A1 (zh) | 用於治療癌症的作為btk抑制劑的吡唑並嘧啶衍生物 | |
IL268340A (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
IL253945B (en) | kdm1a inhibitors to treat the disease | |
IL249281A0 (en) | Cyclopropylamine compounds as histone demethylase inhibitors | |
SI3371190T1 (sl) | Heterociklične spojine kot inhibitorji PI3K gama | |
DK3157527T3 (da) | Ezh2-hæmmere til lymfombehandling | |
IL247721A0 (en) | Pharmaceutical preparations containing active medicinal compounds for the treatment of solid tumors | |
IL278247B (en) | mct4 inhibitors to treat the disease | |
IL254266A0 (en) | Glucosylceramide synthase inhibitors for the treatment of diseases | |
HK1253238A1 (zh) | 用於治療疾病的gls1抑制劑 | |
IL261047A (en) | Taf1 inhibitors for the therapy of cancer | |
PL3164394T3 (pl) | Inhibitory GLS1 do leczenia chorób | |
ZA201701450B (en) | Small molecule inhibitors for cancer therapy | |
IL265342A (en) | Use of pridofidine for the treatment of Rett syndrome | |
EP3152195A4 (en) | Mth1 inhibitors for treatment of cancer | |
HK1257565A1 (zh) | 作為htra1抑制劑的新型三氟甲基丙酰胺衍生物 | |
HK1257567A1 (zh) | 作為htra1抑制劑的新型二氟酮酰胺衍生物 | |
HK1247198A1 (zh) | 作為用於治療癌症的組蛋白脫甲基酶kdm2b的抑制劑的(呱啶-3-基)(萘-2-基)甲酮衍生物及其相關化合物 | |
PL3364971T3 (pl) | Heterocykliczne inhibitory PDK1 do zastosowania w leczeniu nowotworu | |
GB201414028D0 (en) | Small molecule inhibitors for cancer therapy |